0NN Stock Overview A commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Avicanna Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Avicanna Historical stock prices Current Share Price CA$0.20 52 Week High CA$0.38 52 Week Low CA$0.15 Beta 1.66 1 Month Change 12.36% 3 Month Change -3.85% 1 Year Change -16.67% 3 Year Change -61.54% 5 Year Change -89.87% Change since IPO -90.96%
Recent News & Updates
Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023) Nov 17 Avicanna Inc. announced that it has received CAD 0.80001 million in funding Nov 05
Avicanna Inc. announced that it has received CAD 1.986208 million in funding Aug 29
Second quarter 2024 earnings released: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023) Aug 16
Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology Jun 19
Avicanna Inc., Annual General Meeting, Jul 10, 2024 Jun 05 See more updates
Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023) Nov 17 Avicanna Inc. announced that it has received CAD 0.80001 million in funding Nov 05
Avicanna Inc. announced that it has received CAD 1.986208 million in funding Aug 29
Second quarter 2024 earnings released: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023) Aug 16
Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology Jun 19
Avicanna Inc., Annual General Meeting, Jul 10, 2024 Jun 05
Insider recently bought €169k worth of stock May 29
First quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.033 loss in 1Q 2023) May 15
Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa May 15 Avicanna Inc. announced that it has received CAD 2.125584 million in funding Apr 19
Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study Apr 10
Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022) Apr 03
Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation Mar 28
Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024 Mar 27
Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox Feb 15 Avicanna Inc. announced that it has received CAD 0.888128 million in funding Dec 05
Less than half of directors are independent Nov 24
Third quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.048 loss in 3Q 2022) Nov 19
Avicanna Announces Appointment of Paul Fornazzari to Board of Directors Nov 14
Avicanna Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 02
Avicanna Inc. Provides Update on the Successful Launch of MyMedi.ca Oct 12
Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors Sep 02
Second quarter 2023 earnings released: CA$0.021 loss per share (vs CA$0.08 loss in 2Q 2022) Aug 17 Avicanna Inc. announced that it has received CAD 1.455 million in funding Aug 03
Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. Aug 02
Avicanna Inc. (TSX:AVCN) entered into definitive Asset Purchase Agreement to acquire Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. for CAD 2.6 million. May 30
First quarter 2023 earnings released: CA$0.033 loss per share (vs CA$0.02 loss in 1Q 2022) May 17
Insider recently bought €90k worth of stock Jan 05
Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023 Dec 31 Avicanna Inc. announced that it has received CAD 1.769097 million in funding
Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the Rho Phytotm Cbg Transdermal Gel Topical Product Dec 15
Avicanna Inc. Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market Nov 30
Insider recently bought €388k worth of stock Nov 27
Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021) Nov 13 Avicanna Inc. announced that it has received CAD 0.626763 million in funding Nov 12
Avicanna Files Complete Patent Specifications Relating to A Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy Oct 21
Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals Oct 19
Assad Kazeminy Retires as Director of Avicanna Inc Sep 02
Second quarter 2022 earnings released: CA$0.08 loss per share (vs CA$0.067 loss in 2Q 2021) Aug 18 Avicanna Inc. announced that it has received CAD 2.782302 million in funding Aug 18
Avicanna Inc., Annual General Meeting, Aug 31, 2022 Jul 06
An unknown buyer acquired 63 percent stake in Sativa Nativa S.A.S. from Avicanna Inc. (TSX:AVCN) for CAD 0.81 million. Jun 25
Forecast to breakeven in 2024 May 18
First quarter 2022 earnings released: CA$0.02 loss per share (vs CA$0.085 loss in 1Q 2021) May 15
Avicanna Inc. Announces Chief Financial Officer Changes May 13 Avicanna Inc. announced that it has received CAD 1.473826 million in funding from Ei.Ventures, Inc. May 08
Full year 2021 earnings released: CA$0.41 loss per share (vs CA$1.12 loss in FY 2020) Apr 02 Avicanna Inc. announced that it has received CAD 2.523568 million in funding Apr 01
Shareholder Returns 0NN DE Pharmaceuticals DE Market 7D -7.4% 1.4% 0.5% 1Y -16.7% -16.3% 7.2%
See full shareholder returns
Return vs Market: 0NN underperformed the German Market which returned 7% over the past year.
Price Volatility Is 0NN's price volatile compared to industry and market? 0NN volatility 0NN Average Weekly Movement 19.3% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0NN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0NN's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.
Show more Avicanna Inc. Fundamentals Summary How do Avicanna's earnings and revenue compare to its market cap? 0NN fundamental statistics Market cap €23.46m Earnings (TTM ) -€4.52m Revenue (TTM ) €16.56m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0NN income statement (TTM ) Revenue CA$24.90m Cost of Revenue CA$13.73m Gross Profit CA$11.17m Other Expenses CA$17.97m Earnings -CA$6.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.062 Gross Margin 44.86% Net Profit Margin -27.32% Debt/Equity Ratio 0.9%
How did 0NN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 18:32 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Avicanna Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Rahul Sarugaser Raymond James Ltd.
Show 0 more analysts 
